McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,379 |
Corporate Governance Statement and Appendix 4G
|
28 Aug 2025 5:23PM |
$17.920 |
$19.800 |
risen by
10.49%
|
|
NeuroScientific Biopharmaceuticals Ltd (NSB) ORDINARY FULLY PAID |
Health Care |
$53 |
2025 Annual Report & Appendix 4E
|
28 Aug 2025 5:23PM |
$0.160 |
$0.160 |
fallen by
0%
|
|
NSB - Price-sensitive ASX Announcement
Full Release
Key Points
- NSB is focused on the development of peptide-based therapies for neurodegenerative diseases.
- The lead drug candidate, EmtinB, showed promising results in preclinical studies targeting Alzheimer's, Multiple Sclerosis, and optic nerve injury.
- During the year, NSB advanced towards first-in-human clinical trials, receiving necessary ethics approvals.
- Financial results indicate a net loss for the reporting period, with disciplined cost control measures in place.
- NSB maintains a strong cash balance to fund ongoing research and development activities.
- Corporate governance and risk management frameworks are in place, reflecting ASX and regulatory compliance.
- The company is committed to sustainable business practices and responsible operations.
- Future strategy centers on progressing clinical trials of EmtinB and potentially broadening the therapeutic pipeline.
- No dividends were declared or paid during the period.
- Shareholder value creation and clinical development remain central to NSB’s strategic outlook.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$738 |
Appendix 4G
|
28 Aug 2025 5:22PM |
$1.290 |
$1.265 |
fallen by
1.94%
|
|
McMillan Shakespeare Limited (MMS) ORDINARY FULLY PAID |
Industrials |
$1,379 |
Appendix 4E and Annual Report to Shareholders
|
28 Aug 2025 5:22PM |
$17.920 |
$19.800 |
risen by
10.49%
|
|
MMS - Price-sensitive ASX Announcement
Full Release
Key Points
- MMS recorded total revenue of $674.2 million, a 9% increase from the previous year.
- Net profit after tax was $78.8 million, representing a 1% increase year-on-year.
- The company’s key business segments are Group Remuneration Services, Asset Management, and Retail Financial Services.
- A final dividend of 29 cents per share, fully franked, was declared.
- MMS continues to invest in digital transformation and improving customer experience.
- The company maintains a strong balance sheet and cash flow position.
- Sustainability and responsible business practices are highlighted as core priorities.
- MMS provides detailed audited financial statements and a director’s report.
- Employee engagement and development remain key focuses for the organization.
- The Annual Report includes information on risk management, governance, and forward-looking guidance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$6,923 |
Appendix 3Y - Matthew Halliday
|
28 Aug 2025 5:21PM |
$29.410 |
$29.050 |
fallen by
1.22%
|
|
Algorae Pharmaceuticals Limited (1AI) ORDINARY FULLY PAID |
Health Care |
$15 |
Annual Report and Appendix 4E
|
28 Aug 2025 5:20PM |
$0.009 |
$0.009 |
fallen by
0%
|
|
1AI - Price-sensitive ASX Announcement
Full Release
Key Points
- Algorae Pharmaceuticals Limited changed its name from Living Cell Technologies Limited during the reported period.
- The company shifted its core focus from cell-based therapies to AI-driven drug discovery and development.
- 1AI is the proprietary AI platform developed to identify and accelerate peptide and protein-based drug discovery.
- The Annual Report covers financial results, corporate governance, board changes, and compliance with regulations.
- Strategic partnerships and international expansion are highlighted as future priorities.
- Research and development expenditures reflect the increased focus on AI and computational drug discovery.
- The company acknowledges risks related to AI technology, regulatory compliance, and market competition.
- The outlook anticipates further integration of AI technologies and continued pursuit of novel therapeutics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$738 |
2025 Annual Report to Shareholders
|
28 Aug 2025 5:18PM |
$1.290 |
$1.265 |
fallen by
1.94%
|
|
Truscott Mining Corporation Limited (TRM) ORDINARY FULLY PAID |
Materials |
$9 |
Change of Director's Interest Notice - PN Smith
|
28 Aug 2025 5:18PM |
$0.043 |
$0.044 |
risen by
2.33%
|
|
Brazilian Critical Minerals Limited (BCM) ORDINARY FULLY PAID |
Materials |
$36 |
Proposed issue of securities - BCM
|
28 Aug 2025 5:17PM |
$0.023 |
$0.023 |
fallen by
0%
|
|
Global X S&P 500 Covered Call ETF (UYLD) |
Financials |
$11 |
Global X Updated Est Distribution Announcement - August 2025
|
28 Aug 2025 5:17PM |
$10.800 |
$10.740 |
fallen by
0.56%
|
|
Global X Nasdaq 100 Covered Call ETF (QYLD) |
Financials |
$20 |
Global X Updated Est Distribution Announcement - August 2025
|
28 Aug 2025 5:17PM |
$11.020 |
$10.960 |
fallen by
0.54%
|
|
Global X Australian Bank Credit ETF (BANK) |
Financials |
$102 |
Global X Updated Est Distribution Announcement - August 2025
|
28 Aug 2025 5:17PM |
$10.020 |
$10.000 |
fallen by
0.20%
|
|
PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$738 |
Appendix 4E
|
28 Aug 2025 5:15PM |
$1.290 |
$1.265 |
fallen by
1.94%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC Therapeutics Limited released its Appendix 4E, which is a preliminary final report for the year ended 31 December 2023.
- The company is engaged in the development of RNA therapeutics, focusing on the treatment of inherited retinal diseases and other genetic disorders.
- There were no dividends paid or recommended during the reporting period.
- The net loss after tax attributable to members for the year was $28,009,000, compared to a net loss after tax of $22,601,000 in the previous year.
- Comprehensive loss for the year attributable to members was $27,977,000, compared to $22,601,000 in the previous year.
- Basic and diluted loss per share were both 2.32 cents, compared to 2.10 cents in the previous year.
- The report provides detailed commentary on the results, including progress of clinical trials, pipeline developments, and financial highlights.
- PYC Therapeutics Limited continues to invest in the development of its therapeutic candidates and anticipates further clinical milestones in the coming periods.
- The Appendix 4E includes the annual financial results, commentary on operations, and outlines significant activities undertaken by the company during the reporting period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Brazilian Critical Minerals Limited (BCM) ORDINARY FULLY PAID |
Materials |
$36 |
Loan Conversion and Raising
|
28 Aug 2025 5:15PM |
$0.023 |
$0.023 |
fallen by
0%
|
|
BCM - Price-sensitive ASX Announcement
Full Release
Key Points
- BCM announced loan conversion and capital raising on 6 June 2024.
- $1.05 million of loans converted into equity at $0.07 per share.
- 15 million shares issued to directors and major shareholders for loan conversion.
- $3.25 million raised through placement of 46.43 million shares at $0.07 per share.
- Placement shares issued to sophisticated and professional investors under Listing Rule 7.1.
- Funds to be used for exploration, development, and working capital for BCM's Brazilian mineral projects.
- Board thanked shareholders and emphasized strategic importance of the funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Ampol Limited (ALD) ORDINARY FULLY PAID |
Energy |
$6,923 |
Notification regarding unquoted securities - ALD
|
28 Aug 2025 5:14PM |
$29.410 |
$29.050 |
fallen by
1.22%
|
|
Health and Plant Protein Group Limited (HPP) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
Business update - HPP and REES
|
28 Aug 2025 5:14PM |
$0.042 |
$0.042 |
fallen by
0%
|
|
Harris Technology Group Limited (HT8) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
FY25 Results Commentary
|
28 Aug 2025 5:11PM |
$0.012 |
$0.012 |
fallen by
0%
|
|
Harris Technology Group Limited (HT8) ORDINARY FULLY PAID |
Consumer Discretionary |
$4 |
Preliminary Final Report
|
28 Aug 2025 5:11PM |
$0.012 |
$0.012 |
fallen by
0%
|
|
HT8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for the year ended 30 June 2023 was $27.65 million, down from $51.12 million in 2022.
- Net loss after tax was $2.91 million, compared to a loss of $2.04 million in the previous year.
- Decline in revenue attributed to post-pandemic e-commerce competition and challenging trading conditions.
- Cost management and operational efficiency initiatives were a focus during the year.
- No dividends were declared for the reporting period.
- HT8 undertook product range expansion and strengthened supplier relationships to adapt to market conditions.
- The company is pursuing strategies to return to profitability through improved sales channels, diversification, and customer service enhancements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Chalice Mining Limited (CHN) ORDINARY FULLY PAID |
Materials |
$692 |
Notification regarding unquoted securities - CHN
|
28 Aug 2025 5:11PM |
$1.745 |
$1.778 |
risen by
1.86%
|
|
Rumble Resources Limited (RTR) ORDINARY FULLY PAID |
Materials |
$28 |
Restricted Securities to be Released from Voluntary Escrow
|
28 Aug 2025 5:08PM |
$0.029 |
$0.029 |
fallen by
0%
|
|
My Foodie Box Limited (MBX) ORDINARY FULLY PAID |
Consumer Staple |
$1 |
Change of Registered Office and Place of Business
|
28 Aug 2025 5:08PM |
$0.004 |
$0.004 |
fallen by
0%
|
|
Polynovo Limited (PNV) ORDINARY FULLY PAID |
Health Care |
$888 |
Change in substantial holding
|
28 Aug 2025 5:07PM |
$1.355 |
$1.285 |
fallen by
5.17%
|
|
Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$436 |
Notification of cessation of securities - PBH
|
28 Aug 2025 5:06PM |
$1.260 |
$1.255 |
fallen by
0.40%
|
|
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$83 |
Appendix 4G & Corporate Governance Statement
|
28 Aug 2025 5:06PM |
$0.640 |
$0.645 |
risen by
0.78%
|
|
Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$83 |
Appendix 4E & Annual Report to 30 June 2025
|
28 Aug 2025 5:05PM |
$0.640 |
$0.645 |
risen by
0.78%
|
|
AGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of Phase 1 clinical trial for ARG-007, demonstrating safety and tolerability in healthy participants
- Initiation of Phase 2a clinical trial in acute ischaemic stroke patients
- Advancement of preclinical studies for traumatic brain injury and hypoxic ischaemic encephalopathy
- Ongoing research and development investment leading to reported loss for the financial year
- Detailed cash flow and funding disclosures, including capital raisings to support clinical progression
- Focus on expanding ARG-007’s indications and progressing clinical and regulatory milestones
- Emphasis on corporate governance, risk management, and strategic planning for future growth
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.